Avian influenza overview June–September 2024
Meta data
Note: This article was originally published on the EFSA website (https://www.efsa.europa.eu/en/efsajournal/pub/9057) on 3 October 2024 as part of EFSA’s urgent publication procedures. On 14 October 2024, on p. 27, the total number of mammals tested in Austria was corrected from 205 to 294. In addition, on p. 47, ‘South American sea lion’ was corrected to ‘Antarctic fur seal’. These editorial corrections do not materially affect the contents or outcome of this scientific output. To avoid confusion, the original version of the output has been removed from the EFSA website, but is available on request.
Abstract
Between 15 June and 20 September 2024, 75 highly pathogenic avian influenza (HPAI) A(H5) and A(H7) virus detections were reported in domestic (16) and wild (59) birds across 11 countries in Europe. Although the overall number of detections in Europe continued to be low compared to previous epidemiological years, an increase in cases along the Atlantic, North Sea and Baltic coasts was notable, particularly an increase in the detection of HPAI viruses in colony‐breeding seabirds. Besides EA‐2022‐BB and other circulating genotypes, these detections also included EA‐2023‐DT, a new genotype that may transmit more efficiently among gulls. In Germany, HPAI A(H7N5) virus emerged in a poultry establishment near the border with the Netherlands. No new HPAI virus detections in mammals were reported in Europe during this period, but the number of reportedly affected dairy cattle establishments in the United States of America (USA) rose to >230 in 14 states, and HPAI virus was identified in three new mammal species. Between 21 June and 20 September 2024, 19 new human cases with avian influenza virus infection were reported from the USA (six A(H5N1) cases and five A(H5) cases), Cambodia (five A(H5N1) cases, including one fatal), China (one fatal A(H5N6) case and one A(H9N2) case), and Ghana (one A(H9N2) case). Most of the human cases (90%, n = 17/19) had reported exposure to poultry, live poultry markets, or dairy cattle prior to avian influenza virus detection or onset of illness. Human infections with avian influenza viruses remain rare and no evidence of human‐to‐human transmission has been documented in the reporting period. The risk of infection with currently circulating avian A(H5) influenza viruses of clade 2.3.4.4b in Europe remains low for the general public in the European Union/European Economic Area (EU/EEA). The risk of infection remains low‐to‐moderate for those occupationally or otherwise exposed to infected animals or contaminated environments.